Clinical trials have demonstrated that brigatinib is effective in shrinking tumors and prolonging progression-free survival in patients with ALK-positive NSCLC. In a study known as the ALTA trial, brigatinib showed a higher response rate compared to crizotinib, making it a valuable option for patients who have developed resistance to first-line therapies.
